Patients with end-stage heart failure benefit from resynchronization therapy with improved symptoms, quality-of-life, exercise endurance and left ventricular ejection fraction, Dutch researchers report.
“Even in a relatively small group of patients, most patients will benefit from biventricular pacing,” principal investigator Dr. Martin J. Schalij told Reuters Health. “I believe this is really a breakthrough therapy for this group of patients with a bad prognosis.”
Dr. Schalij and colleagues from Leiden University Medical Center, studied 40 patients with end-stage heart failure. The patients were New York Heart Association (NYHA) functional class III or IV, with left ventricular ejection fractions of less than 35%, QRS duration of more than 120 ms, and left bundle branch block.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!